Benzatropine
| Error creating thumbnail: File missing | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | oral, IM, IV |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 36 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C21H25NO |
| Molar mass | 307.429 g/mol |
|
WikiDoc Resources for Benzatropine |
|
Articles |
|---|
|
Most recent articles on Benzatropine Most cited articles on Benzatropine |
|
Media |
|
Powerpoint slides on Benzatropine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Benzatropine at Clinical Trials.gov Clinical Trials on Benzatropine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Benzatropine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Benzatropine Discussion groups on Benzatropine Patient Handouts on Benzatropine Directions to Hospitals Treating Benzatropine Risk calculators and risk factors for Benzatropine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Benzatropine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Benzatropine mesilate (INN, commonly known as benztropine; marketed as Cogentin) is an anticholinergic drug principally used for the treatment of:
- Drug-induced parkinsonism, akathisia and acute dystonia;
- Parkinson disease; and
- Idiopathic or secondary dystonia.
Indications
It is used in patients with schizophrenia to reduce the side effects of antipsychotic treatment, such as parkinsonism and akathisia.
Benztropine is also a second-line drug for the treatment of Parkinson's disease. It improves tremor but not rigidity or bradykinesia.
Benztropine is also sometimes used for the treatment of dystonia, a rare disorder that causes abnormal muscle contraction, resulting in twisting postures of limbs, trunk, or face.
Side effects
These are principally anticholinergic:
- Dry mouth
- Blurred vision
- Cognitive changes
- Constipation
- Urinary retention
- Tachycardia
- Anorexia
- Psychosis (usually in overdose)
Some studies suggest that use of anticholinergics increases the risk of tardive dyskinesia, a long-term side effect of antipsychotics.[1][2]
Other studies have found no association between anticholinergic exposure and risk of developing tardive dyskinesia.[3]
References
- ↑ "Arch Gen Psychiatry -- Abstract: Tardive dyskinesia: prevalence and risk factors, 1959 to 1979, April 1982, Kane and Smith 39 (4): 473". Retrieved 2007-08-14.
- ↑ Wszola BA, Newell KM, Sprague RL (2001). "Risk factors for tardive dyskinesia in a large population of youths and adults". Experimental and clinical psychopharmacology. 9 (3): 285–96. PMID 11534539.
- ↑ van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS (1998). "Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III". The American journal of psychiatry. 155 (4): 565–7. PMID 9546009.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs
- Anticholinergics
- Dopamine reuptake inhibitors
- Muscarinic antagonists
- Tardive dyskinesia